close

Syncom Formulations (India) Ltd

Know More
NSEBSE

8.40-0.05 (-0.59%)

12:00 AM,29th Sep 2023

8.39-0.06 (-0.71%)

12:00 AM,29th Sep 2023

BSE : 524470

NSE : SYNCOMF

Sector : Health care

ISIN Code : INE312C01025

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Sep 29 2023 | 12:00 AM IST

Market Cap (₹ Cr)

789

Turnover (₹ Cr)

0.09

Volume (Shares)

1089763

Face Value

1

52-WK High

11.60

52-WK High Date

26 Dec 2022

52-WK Low

4.60

52-WK Low Date

29 Mar 2023

All Time High

11.60

All Time High Date

26 Dec 2022

All Time Low

4.60

All Time Low Date

29 Mar 2023

Syncom Formulations (India) Ltd

Incorporated as a private limited company in 1988 Syncom Formulations (India) was converted into a public limited company in Jun.'92. The company set up a manufacturing facility at Palghar Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda Vijay Kumar Bankda and Ajay Kumar Bankda.In addition to pharmaceutical formulations in the form of tablets capsules liquids and dry powders the company also manufactures injectibles and ear/eye drops on a loan licence basis.In 1994 the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995.During the year 1997-98 the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%.During the year 1999-2000 the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine Ghana Kenya Tanzania Nigeria in Africa Azberjan Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products the company is aggressively manufacturing and marketing its herbal products like Edicare Attom Megacaps Ecziguard and Yas antacid salt.

Syncom Formulations (India) Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

789

EPS - TTM (₹) [S]

0.22

P/E Ratio (X) [S]

3.09

Face Value (₹) 1
Latest Dividend (%)3.00
Latest Dividend Date 09 Sep 2022
Dividend Yield (%) -
Book Value Share (₹) [S]2.72
P/B Ratio (₹) [S]3.09
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Motilal Oswal S&P BSE Healthcare ETF 0.00 4696 0.05

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

8.35

8.55

Week Low/High

8.35

9.00

Month Low/High

8.00

9.00

Year Low/High

4.60

12.00

All time Low/High

0.14

12.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-2.67%-2.33%-0.27-0.18%
1 Month-3.34%-2.89%1.161.53%
3 Month10.24%10.53%2.993.51%
6 Month68.34%68.00%14.2615.85%
1 Year4.48%%16.7016.77%
3 Year402.99%%73.3574.99%

Financials

Graph
Table

Bulk/ Block

ALL
NSE
BSE
ALL
BUY
SELL
DateClient NameExchangeTransactionQuantityPrice
12-01-2022ALPHA LEON ENTERPRISES LLPBSEBUY593196616.31
12-01-2022ALPHA LEON ENTERPRISES LLPBSESELL610067317.46
04-01-2022PRITESH PRAVIN VORABSESELL421397014.46
04-01-2022PRITESH PRAVIN VORABSEBUY421397013.48
12-10-2021TOPGAIN FINANCE PRIVATE LIMITEDBSEBUY460112712.89
12-10-2021TOPGAIN FINANCE PRIVATE LIMITEDBSESELL628174013.05
21-06-2021ALPHA LEON ENTERPRISES LLPBSESELL61134748.75
21-06-2021ALPHA LEON ENTERPRISES LLPBSEBUY69571648.44
01-06-2021TOPGAIN FINANCE PRIVATE LIMITEDBSEBUY71255197.84
01-06-2021TOPGAIN FINANCE PRIVATE LIMITEDBSESELL77685097.87

Load More

Peer Group Comparison

NamePrice(In Rs)Chg(%)Mkt Cap(Rs Cr)Sales(Rs Cr)Profit(Rs Cr)EPS(Rs)P/E(x)

Shareholding Pattern

Jun 2023
Archive
CategoryShare(%)
Promoter50.57
Financial Institutions Banks0.00
Foreign Institutional Investors0.00
Insurance Companies0.00
Mutual Funds Uti0.00
Other Institutional Investors0.00
Indian Public45.00
Others Non Institutional Investors4.43
Custodians0.00

Corporate Action

Announcement DatePurposeFromToRemarks
Data Not Found

Price History

Search for Price History

DateOpenHighLowCloseSharesTrades
Data Not Found

Load more

Company Info

Company Information

Chairman & Wholetime Director : Kedarmal Bankda

Managing Director : Vijay Shankarlal Bankda

Independent Director : Vinod Kumar Kabra

Independent Director : Krishna Das Neema

Independent Director : Praveen Jindal

Whole-time Director : Rinki Bankda

Addtnl Independent Director : Ruchi Jindal

Company Sec. & Compli. Officer : Vaishali Agrawal

Registered Office: 7 Niraj Indl Estate Andheri(E), Off Mahakali Caves Rd,Mumbai,Maharashtra-400093 Ph: 91-22-30887744

Email:info@sfil.in / finance@sfil.in

URL:http://www.sfil.in